OBI-3424 Uses, Dosage, Side Effects and more
OBI-3424 is under investigation in clinical trial NCT04315324 (Study to Test Akr1c3-activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)).
| Trade Name | OBI-3424 |
| Generic | OBI-3424 |
| Type | |
| Formula | C21H25N4O6P |
| Weight | Average: 460.427 Monoisotopic: 460.151171539 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
